



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
475 ALLENDALE ROAD
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

April 19, 2005

Docket No. 030-13723
Control No. 136526

License No. 37-17938-01

Garvin Bixler, Ph.D.
Platform Leader
Sanofi Pasteur, Inc.
Discovery Drive
Swiftwater, PA 18370-0187

SUBJECT: SANOFI PASTEUR, INC., REQUEST FOR ADDITIONAL INFORMATION
CONCERNING APPLICATION FOR RENEWAL OF LICENSE, CONTROL NO.
136526

Dear Dr. Bixler:

This is in reference to your application dated February 28, 2005 requesting to renew Nuclear Regulatory Commission License No. 37-17938-01. In order to continue our review, we need the following additional information:

1. The company name on the license has changed. Please provide a complete description of the transaction (transfer of stocks or assets, or merger). Include the name and telephone number of a licensee contact who NRC may contact if more information is needed.
2. Describe any changes in the organization that relate to the licensed program.
3. Confirm that the transferee will abide by all constraints, conditions, requirements and commitments of the transferor.
4. Describe all rooms being utilized for licensed material within Building 53. Include a description of the area(s) assigned for the receipt, storage, preparation and measurement of radioactive materials. Submit a diagram showing the locations of shielding, the proximity of radiation sources to unrestricted areas, and other items related to radiation safety. Where licensed material may become airborne, the diagrams should contain schematic descriptions of the ventilation systems, with pertinent airflow rates, pressures, filtration equipment, and monitoring systems. Diagrams should be drawn to a specified scale, or dimension should be indicated.

Current NRC regulations and guidance are available at the NRC Web sites listed below or by contacting the Government Printing Office (GPO) toll-free at 1-888-293-6498. The GPO is open from 7:00 a.m. to 9:00 p.m. EST, Monday through Friday (except Federal holidays).

We will continue our review upon receipt of this information. Please reply to my attention at the Region I Office and refer to Mail Control No. 136526. If you have any technical questions regarding this deficiency letter, please call me at (610) 337-5366.

G. Bixler
Sanofi Pasteur, Inc.

2

In order to continue prompt review of your application, we request that you submit your response to this letter within 30 calendar days from the date of this letter.

Sincerely,

Original signed by Thomas K. Thompson

Thomas K. Thompson
Senior Health Physicist
Commercial and R&D Branch
Division of Nuclear Materials Safety

Enclosure:

NRC Web site addresses

NRC regulations

<http://www.nrc.gov/reading-rm/doc-collections/cfr/>

Licensing guidance

<http://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/>

General Policy and Procedure for NRC Enforcement Actions

<Http://www.nrc.gov/what-we-do/regulatory/enforcement/enforc-pol.pdf>

206 of the Energy Reorganization Act of 1974

<http://www.nrc.gov/who-we-are/governing-laws.html>

G. Bixler
Sanofi Pasteur, Inc.

3

DOCUMENT NAME: E:\Filenet\ML051100014.wpd

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	N	DNMS/RI		DNMS/RI			
NAME	TThompson/TKT							
DATE	4/19/2005							

OFFICIAL RECORD COPY